When pembrolizumab was added to paclitaxel with or without bevacizumab in platinum-resistant ovarian cancer, significant ...

Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...

These data support the use of pembrolizumab plus weekly paclitaxel, with or without bevacizumab, as a new standard of care for patients with platinum-resistant, recurrent ovarian cancer,” said ...

GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R ...

Prestigious European Society for Medical Oncology Conference “trials-in-progress” sessionPivotal OVATION 3 trial of its DNA-mediated ...

Veteran actor Nafisa Ali, known for her memorable role in ‘Life in a Metro’ and many movies, has restarted chemotherapy as ...

The European Society for Medical Oncology "Living Guideline" for Gastric Cancer suggests that narrow-band imaging or ...

Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 ...

New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression OSLO, Norway, Oct. 8, 2025 /PRNewswire/ -- Oncoinvent ASA, a ...